Search PGEN
PRECIGEN, INC.
Nasdaq · CIK 1356090
Last close8.54
Daily change+0.33 (4.02%)
10 Years gain-70.33%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PGEN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
34.6Momentum
n/aAcceleration
n/aConfidence
83.0Annual Revenue15
Quarterly Revenue58
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.1 / 25
Quality5.3 / 25
Capital Efficiency0.0 / 20
Balance Sheet11.1 / 15
Shareholder Economics5.3 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Negative FCF · HIGHLatest free cash flow is negative.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM245.91%OK
Revenue CAGR 3Y-28.87%OK
Gross Margin100%OK
Operating Margin-46.89%OK
FCF Margin-123.31%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-30.78%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO-0.57xOK
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenue13.55%OK
SBC / FCF-10.99%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $9.68M | $9.68M | -$110.51M | -$87.83M | -$89.83M | 100% | -1,141.13% | -927.57% | n/a | 312.98M |
| 2025 FY Dec 31, 2024 | $3.93M | $3.93M | -$135.03M | -$68.17M | -$76.76M | 100% | -3,440.23% | -1,955.59% | n/a | 267.73M |
| 2025 FY Dec 31, 2023 | $6.23M | $6.23M | -$99.76M | -$66.93M | -$68.47M | 100% | -1,602.54% | -1,099.86% | -70.01% | 244.54M |
| 2024 FY Dec 31, 2022 | n/a | n/a | n/a | -$65.05M | -$69.97M | n/a | n/a | n/a | n/a | 200.36M |
| 2022 FY Dec 31, 2022 | $26.91M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $80.43M | sum latest 4 fiscal quarters Revenue | OK | 0001356090-26-000017, 0001356090-26-000030 |
| Revenue Growth TTM | 245.91% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001356090-26-000017, 0001356090-26-000030 |
| Revenue CAGR 3Y | -28.87% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001356090-26-000009 |
| Revenue CAGR 5Y | -21.26% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001356090-26-000009 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001356090-26-000009 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001356090-26-000017, 0001356090-26-000030 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0001356090-26-000017, 0001356090-26-000030 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001356090-26-000017, 0001356090-26-000030 |
| Operating Margin | -46.89% | Operating Income / Revenue | OK | 0001356090-26-000017, 0001356090-26-000030 |
| FCF Margin | -123.31% | (CFO - CapEx) / Revenue | OK | 0001356090-26-000017, 0001356090-26-000030 |
| ROIC | -30.78% | NOPAT / Average Invested Capital | OK | 0001356090-26-000017, 0001356090-26-000030 |
| Net Debt / CFO | -0.57x | Net Debt / CFO | OK | 0001356090-26-000030, 0001356090-26-000017 |
| Current Ratio | 4.58x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.41x | (Cash + Short-term Investments) / Total Debt | OK | 0001356090-26-000030 |